-+ 0.00%
-+ 0.00%
-+ 0.00%

Anika Therapeutics publishes 2025 annual report on Form 10-K

PUBT·04/30/2026 19:48:29
Listen to the news
Anika Therapeutics publishes 2025 annual report on Form 10-K
  • Anika Therapeutics filed its annual report for fiscal year ended Dec. 31, 2025, highlighting a strategic shift to focus on OA Pain Management and Regenerative Solutions.
  • Portfolio reshaping continued with sale of Arthrosurface on Oct. 31, 2024 for a $7 million non-interest bearing promissory note plus potential contingent payments.
  • Parcus Medical divestiture closed on March 7, 2025 for USD 4.5 million cash, completing exit from businesses acquired under prior strategy.
  • Product pipeline advanced with Hyalofast PMA submitted Oct. 31, 2025, followed by an FDA deficiency letter in January 2026 that Anika is preparing to address.
  • U.S. growth plan centered on Integrity Implant System adoption, while Cingal remained unapproved in U.S. as work continued on studies tied to an eventual regulatory submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anika Therapeutics Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.